Company / EPS (Diluted)
Caribou Biosciences, Inc. EPS (Diluted) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.65
FY2025
5-year range
-$2.80 / -$1.38
FY2021-FY2025
Trend
-19.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
-1.65 in FY2025.
Remained stable around $-1.65 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 19.6% year-over-year.
- Peak eps (diluted) was recorded in FY2024.
- Lowest eps (diluted) in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.65 | -19.6% |
| FY2024 | -$1.38 | +15.9% |
| FY2023 | -$1.64 | +22.3% |
| FY2022 | -$2.11 | +24.6% |
| FY2021 | -$2.80 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026